Top Stock Movers Today — August 6, 2026: Why WYHG, IOVA, HNST, ASPN & INSM Surged

WYHG — Wing Yip Food Holdings Group Ltd (+197.0%)

Wing Yip Food Holdings Group (WYHG) nearly tripled on August 6, closing at $9.92 on volume of 14,293,661 shares — roughly 18.7× its 20-day average of 765,278. The stock also gapped up +147.6% at the open, meaning the lion's share of the gain was priced in before most retail traders could react.

Why it moved: No specific news headline or SEC filing explains Thursday's explosion. With no catalyst on file beyond a routine 6-K filed on July 22, this move appears to be momentum- and technically-driven, likely amplified by the stock's very thin float. When a low-float stock — one with a small number of shares freely tradeable by the public — sees a sudden surge in buy orders, even modest demand can send the price rocketing because there are so few shares available to absorb it.

The StockSetups scan flagged WYHG with a conviction score of 100/100 and a grade of A+, a perfect technical rank of 100, and an RS (relative strength) rating of 99 — meaning it outperformed virtually every other stock in the US universe over the trailing period. The inverted hammer candlestick that printed today can signal a potential reversal after a climactic move, so traders following this name should treat the chart with extra caution. RSI closed at 82, deep in overbought territory. Moves of this magnitude in small, low-float foreign issuers frequently reverse sharply; the $172M market cap and the absence of a confirmed fundamental catalyst make this one of the riskiest names in today's recap.

IOVA — Iovance Biotherapeutics (+42.4%)

Iovance Biotherapeutics (IOVA) surged +42.4% to close at $6.18, with 75,333,316 shares changing hands — nearly 4× its 20-day average of 19,413,691. The stock gapped up +38.3% at the open and closed at a fresh 52-week high.

Why it moved: Iovance reported record second-quarter 2026 revenue of approximately $99 million, according to the company's earnings release covered by Yahoo Finance on August 6. For a commercial-stage cell-therapy company still climbing toward profitability, a revenue record signals that its TIL (tumor-infiltrating lymphocyte) therapy commercial ramp is genuinely accelerating — that's the kind of inflection point that sends institutional money rushing in. The headline beat was reinforced by positive business and corporate updates in the same release.

From a technical standpoint, StockSetups assigned IOVA a conviction score of 90/100, a grade of A+, and a technical rank of 97. RSI hit 70 — right at the classic overbought threshold — while the moving-average stack is bullish. The largest disclosed institutional stake stands at 7.5%, and a Schedule 13G/A was filed on July 28 reflecting a recent position change, suggesting at least one large investor had been building ahead of earnings. An RS rating of 93 confirms IOVA was already outperforming most peers before today's catalyst. Earnings-gap plays carry significant reversal risk if the euphoria fades; manage position size accordingly.

HNST — The Honest Company (+40.8%)

The Honest Company (HNST) closed up +40.8% at $5.42 on 38,295,087 shares — an extraordinary 12.5× its 20-day average of 3,052,425. The stock gapped +27.0% at the open and hit a 52-week high at the close.

Why it moved: Honest delivered a strong Q2 2026 earnings report, with multiple outlets on August 6 highlighting record margins and a beat on both earnings and revenue estimates. Yahoo Finance and Marketbeat both flagged the Q2 earnings call highlights, with the record-margin story being the headline takeaway. For a consumer-goods brand that has faced margin pressure since going public, demonstrating that it can scale profitably is a meaningful turning point for investor sentiment.

StockSetups rated HNST with a conviction score of 94/100 and a grade of A+. Technical rank came in at 97, and the RS rating was 90. The moving-average stack is bullish and RSI closed at 83, firmly overbought. An ADX of 19 suggests the underlying trend momentum was not extreme coming in, which makes the size of the gap-and-go even more notable — it was driven almost entirely by the earnings surprise rather than a pre-existing hot trend. The 10-Q and 8-K filed August 5 confirm the numbers are in the public record. Volume at more than 12× normal is a strong signal of institutional participation, but extended gap-ups on earnings are notoriously difficult to chase — they can consolidate or reverse just as fast.

ASPN — Aspen Aerogels (+37.3%)

Aspen Aerogels (ASPN) surged +37.3% to close at $6.88 on volume of 9,329,785 shares — about 6.8× its 20-day average of 1,366,662. The stock gapped +47.3% at the open, though it closed below the initial gap high, finishing 22.0% below its 52-week high.

Why it moved: Aspen Aerogels reported Q2 2026 results that beat revenue estimates even as the company posted a net loss — the loss came in $0.05 worse than analyst expectations on earnings per share, but the revenue beat was the market's focus, per MarketBeat and Investing.com coverage on August 6. Crucially, the company also updated its Q3 2026 earnings guidance, signaling confidence in the near-term outlook. MarketBeat specifically noted that shares gapped up after the better-than-expected earnings print. Kalkine Media also highlighted Aspen's relevance to the Russell 1000 index, adding an index-rebalancing angle to the story.

StockSetups scored ASPN at conviction 88/100, grade A+, and technical rank 96. RSI closed at 71, and the moving-average stack is bullish. The trend-template score of 5 (out of 8) is more moderate than the other top gainers today, reflecting that ASPN sits 22% below its 52-week high — so while earnings catalyzed a big gap, the stock is recovering from a deeper base rather than breaking into entirely new territory. That distinction matters for traders assessing whether today's move is a true breakout or a bounce. The revenue beat plus guidance update is a two-punch catalyst, but earnings gaps have a habit of fading; the intraday close below the gap high is worth watching.

INSM — Insmed Inc (+33.9%)

Insmed (INSM) closed up +33.9% at $132.60 on 19,773,634 shares — roughly 5.7× its 20-day average of 3,459,645. The stock gapped +29.4% at the open. With a market cap of $21.4 billion, INSM is by far the largest company in today's recap — and large-cap stocks don't move 34% without a compelling fundamental trigger.

Why it moved: Insmed reported Q2 2026 financial results that beat revenue estimates, even as the company posted a net loss, according to Yahoo Finance coverage on August 6. The revenue beat for a commercial-stage rare-disease biotech signals that its lead asset's commercial trajectory is stronger than consensus expected. That type of positive revenue surprise in a market cap this size typically requires significant institutional buying to produce a 34% single-day move.

Despite the strong price action, StockSetups' signals are notably more cautious here. The conviction score is just 38/100, the grade is D, and the technical rank is 50 — reflecting the fact that INSM's moving-average stack is mixed (not uniformly bullish) and it remains 37.3% below its 52-week high. The trend-template score of 2 is low, meaning the longer-term technical structure is not set up like a classic breakout. RSI hit 76, indicating overbought conditions. Baron Health Care Fund's publicly stated bullish view on Insmed (noted by Yahoo Finance on August 4) may have primed sentiment ahead of earnings. Two insider Form 144 sale notices filed in July are a routine flag worth noting, though not necessarily bearish on their own. The gap here looks far more like a fundamental re-rating off a deep base than a technical breakout — a meaningful distinction for how quickly the move might be sustained or faded.

The bottom line

Today's five biggest gainers were driven by a mix of earnings catalysts and momentum. IOVA, HNST, ASPN, and INSM all gapped up on Q2 2026 results that beat revenue expectations — proof that for mid- and small-cap growth stocks, a quarterly beat can still deliver a single-day move that outpaces months of normal trading. WYHG was the outlier: a near-triple with no confirmed fundamental catalyst, a hallmark of the low-float momentum moves that can appear in any session.

A frank risk reminder: chasing stocks that have already surged 30–200% in a single session is among the highest-risk strategies in the market. Earnings gaps frequently give back a significant portion of their move in the days that follow as early buyers take profits. Momentum names with tiny floats and no clear catalyst can reverse even faster. Short squeezes — where traders betting against a stock are forced to buy to cover losses, amplifying the move — can unwind violently once the buying pressure exhausts. None of the above constitutes financial advice or a recommendation to buy or sell any security. Always do your own research, understand your risk tolerance, and use proper position sizing.

StockSetups scans the full ~12,300-stock US universe after every market close, detecting chart patterns confirmed by candlesticks, computing conviction scores, and sorting setups into actionable lanes — so you can see which names are setting up, breaking out, or retesting before the next session opens. Check back for tomorrow's premarket recap. For more on reading volume context, see our guide to Relative Volume (RVOL). Yesterday's biggest movers are covered in the August 5, 2026 recap.